These data demonstrate that cryptolepine has the ability to activate the metabolic tumor suppressor and disrupt energy homeostasis signaling under in vivo conditions and suggest that it does so by modulating cross-talk between AMPKα1/2 and mTOR cross-talk. Here, PRKAA1 is linked to neoplasm.